- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03827434
CGM/Clarity Use, Glycemic Control and Clinical Outcomes
Improving Glycemic Control and Clinical Outcomes in Insulin Treated DM2 Patients Managed With CGM Devices and Clarity, a Randomized Clinical Trial
The prevalence of Diabetes Mellitus (DM) is rising and more than 30 million of Americans or 9.4% of the US population has DM. Several large scale randomized clinical trials have found that improved glycemic control reduces the development of complications in patients with DM. However intensive glucose management carries an increased risk of hypoglycemia, a condition that may lead to neurological damage and is associated with increased incidence of cardiovascular events and mortality.
Reducing uncontrolled hyperglycemia and hypoglycemia represents therefore an important objective, as may decrease the direct and indirect impact that diabetes has in our health care system. Achieving optimal glycemic control requires frequent blood glucose monitoring by the patients and recurrent clinic visits,which is often difficult to achieve, as access to typical DM clinic is at least sub optimal.
m-Health and telemedicine health solutions represent alternative ways to manage patients in the outpatient setting and have been applied in different medical areas, among them in diabetes. However, almost all the telemedicine studies that have been previously performed and recruited DM patients used telemedicine solutions which were based on point of care (POC) finger-stick glucose testing, which are checked infrequently , usually 4-6 times/day.
Continuous glucose monitoring (CGM) devices offer additional ways to monitor blood glucose values and can provide numerous glucose measurements (as frequent as every 5 min). By using software applications, such as the Clarity (Dexcom), which highlights glucose patterns, trends and statistics in standardized reports, providers can make safe recommendations of adjusting DM medications, especially insulin titration. In this randomized clinical trial investigators propose to use CGM devices and Clarity software as a telemedicine platform in order to improve glycemic control and improve health outcomes.
Study Overview
Status
Conditions
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Baltimore VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- History of Diabetes Mellitus type 2 (DM2) on insulin
- Uncontrolled glycemic control [hyperglycemia defined as Hba1c≥9% in the last 3 months or clinically important hypoglycemia (any reported glucose values less than 54 mg/dl) or severe hypoglycemia (low glucose value that led to a severe event characterized by altered mental status and or physical status requiring assistance)]
Exclusion Criteria:
- Subjects that have a history of type 1 DM
- History of type 2 DM, not treated or required to be treated with basal/bolus insulin (i.e diet only, any combination of non insulin antidiabetic drugs only, basal only insulin or bolus/short acting only insulin, or pre-mixed insulins) as these patients are less likely to benefit from CGM use.
- Pregnant patients
- Use of Clarity/ Share or follow applications as telehealth/telemedicine to improve DM management during the last 3 months prior to study entry.
- Extensive skin changes/disease or allergies that preclude wearing the CGM sensor
- Significant psychiatric illness or any mental condition rendering the subject incapable of understanding the objectives and potential consequences of the study.
- Subjects without personal computer and internet network access.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Continuous glucose Monitoring and Clarity
Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
|
Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
|
Placebo Comparator: Point of Care Fingerstick Glucose values
Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
|
Testing Blood Glucose levels with Point of Care (POC) blood glucose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hemoglobin A1c (HbA1c) among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care)
Time Frame: Through study completion, 6 months after randomization
|
Through study completion, 6 months after randomization
|
Change in the number of hypoglycemic episodes among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care)
Time Frame: Through study completion, 6 months after randomization
|
Through study completion, 6 months after randomization
|
Change in the number of hospitalizations among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care)
Time Frame: Through study completion, 6 months after randomization
|
Through study completion, 6 months after randomization
|
Change in the number of ED visits among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care)
Time Frame: Through study completion, 6 months after randomization
|
Through study completion, 6 months after randomization
|
Change in mortality among participants who are managed with Continuous Glucose Monitoring Devices and Clarity versus participants who are managed with Point of Care glucose testing (standard of care)
Time Frame: Through study completion, 6 months after randomization
|
Through study completion, 6 months after randomization
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00084458
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland
Clinical Trials on Point of Care (POC) blood glucose
-
University of Maryland, BaltimoreDexCom, Inc.CompletedDiabetes MellitusUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
VA Office of Research and DevelopmentRecruitingDiabetes Mellitus, Type 2 | HypoglycemiaUnited States
-
Elizabeth Glaser Pediatric AIDS FoundationUNITAIDCompletedHIV Infections | HIV/AIDS | Infant Morbidity | Perinatal HIV InfectionZimbabwe
-
Sherief Abd-ElsalamRecruitingEndotracheal Tube Wrongly Placed During Anesthetic ProcedureEgypt
-
The University of Texas Health Science Center,...TerminatedAmniotic Fluid; Disorder | Fetal Growth AbnormalityUnited States
-
Loma Linda UniversityCompletedEndotracheal Tube Wrongly Placed During Anesthetic ProcedureUnited States
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério... and other collaboratorsActive, not recruitingHIV, Neonatal HIV Early-Infant-Diagnosis (EID), Point-of-Care Testing (PoC)Mozambique, Tanzania